This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cataracts/ Lens  • Endophthalmitis  • Alert me on articles by topic

Susanna S. Park, MD, PhD; Robert V. Vallar, MD; Chian Huey Hong, MD; Sylviane von Gunten, MD; Kate Ruoff, PhD; Donald J. D'Amico, MD

Arch Ophthalmol. 1999;117:1058-1062.

Objective  To determine whether intravitreal dexamethasone administration can alter the elimination of intravitreal vancomycin hydrochloride in rabbit eyes with experimental Streptococcus pneumoniae endophthalmitis.

Methods  Albino rabbits were infected with an intravitreal inoculum of S pneumoniae (2x10³colony-forming units) and randomized after 24 hours to treatment with intravitreal vancomycin hydrochloride (1 mg), alone or in combination with intravitreal dexamethasone (400 µg). For comparison, uninfected eyes were similarly treated. All eyes were enucleated 24, 48, or 72 hours after treatment, and vitreous levels of vancomycin were quantitated using a fluorescence polarizing immunoassay.

Results  The half-life of intravitreal vancomycin in infected eyes was prolonged from 48 to 84 hours when eyes were treated with dexamethasone. Conversely, such treatment shortened the half-life in uninfected eyes from 56 to 42 hours.

Conclusions  Intravitreal dexamethasone administration reduces the elimination of intravitreal vancomycin in rabbit eyes with pneumococcal endophthalmitis, whereas an opposite effect is noted in uninfected eyes.

Clinical Relevance  In patients with eyes having endophthalmitis caused by virulent organisms, the elimination of intravitreal vancomycin may be reduced when intraocular inflammation is minimized with corticosteroid therapy. This may enhance the efficacy of intravitreal vancomycin therapy in treating the infection.

From the Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas (Drs Park, Vallar, and Hong); and the Retina Service, Massachusetts Eye and Ear Infirmary (Drs von Gunten and D'Amico), and the Clinical Microbiology Laboratory, Massachusetts General Hospital (Dr Ruoff), Boston. Dr Park is now with the Retina Department, The Permanente Medical Group Inc, Sacramento, Calif. Dr von Gunten is now with the Department of Ophthalmology, Geneva University Hospital, Geneva, Switzerland.

RELATED ARTICLE

Vancomycin Concentration in the Vitreous After Intravenous and Intravitreal Administration for Postoperative Endophthalmitis
Joseph R. Ferencz, Ehud I. Assia, Leah Diamantstein, and Ethan Rubinstein
Arch Ophthalmol. 1999;117(8):1023-1027.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Toward Improving Therapeutic Regimens for Bacillus Endophthalmitis
Wiskur et al.
IOVS 2008;49:1480-1487.
ABSTRACT | FULL TEXT  

Bacterial Endophthalmitis: Epidemiology, Therapeutics, and Bacterium-Host Interactions
Callegan et al.
Clin. Microbiol. Rev. 2002;15:111-124.
ABSTRACT | FULL TEXT  

Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis
Gan et al.
Br. J. Ophthalmol. 2001;85:1289-1293.
ABSTRACT | FULL TEXT